CYAN logo

Cyanotech Corporation (CYAN) Análisis de Acciones

Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

CYAN representa a Cyanotech Corporation, una empresa del sector Consumer Defensive con un precio de $ (capitalización de mercado 0). Calificado con 40/100 (cauteloso) en potencial de crecimiento, salud financiera e impulso.

Ultimo analisis: 16 mar 2026
Puntuación de IA de 40/100

Cyanotech Corporation (CYAN) Descripción General del Negocio al Consumidor

CEOMatthew Keith Custer
Empleados77
Sede CentralKailua-Kona, US
Año de la oferta pública inicial (OPI)1991

Cyanotech Corporation, founded in 1983, specializes in microalgae-derived products like BioAstin and Spirulina, catering to the health and wellness market. With a focus on dietary supplements, the company distributes through diverse channels, including online, retail, and bulk sales, positioning itself within the competitive packaged foods sector.

Procedencia de los datos | Datos financieros Análisis cuantitativo NASDAQ Análisis: 16 mar 2026

Tesis de Inversión

Cyanotech Corporation presents a unique investment proposition within the consumer defensive sector, specifically in the niche market of microalgae-derived health supplements. The company's focus on BioAstin and Spirulina products caters to the growing demand for natural antioxidants and dietary supplements. However, with a negative P/E ratio of -1.35 and a negative profit margin of -7.1%, the company's current profitability is a concern. The gross margin of 32.1% indicates potential for improvement in operational efficiency. Key growth catalysts include expanding distribution channels and increasing consumer awareness of the health benefits of astaxanthin and spirulina. The company's low beta of -0.21 suggests relatively low volatility compared to the market, but investors should carefully consider the risks associated with OTC-traded companies.

Basado en las finanzas de FMP y el análisis cuantitativo

Puntos clave

  • Gross Margin of 32.1% indicates potential for profitability improvements through operational efficiencies.
  • Negative Profit Margin of -7.1% signals challenges in achieving sustainable profitability.
  • Market Cap of $0.00B reflects the company's small size and potential for growth or volatility.
  • P/E Ratio of -1.35 indicates the company is currently not profitable, requiring further investigation into its earnings potential.
  • Beta of -0.21 suggests the stock is less volatile than the market, potentially offering stability in turbulent times.

Competidores y Pares

Fortalezas

  • Established brand recognition for BioAstin and Spirulina.
  • Proprietary cultivation and extraction processes.
  • Direct-to-consumer sales channel.
  • Unique Hawaiian origin provides a marketing advantage.

Debilidades

  • Negative profit margin.
  • Limited financial resources compared to larger competitors.
  • Reliance on a small number of key products.
  • Vulnerability to fluctuations in raw material costs.

Catalizadores

  • Ongoing: Expansion of online sales channels to reach a broader customer base.
  • Ongoing: Strategic partnerships with retailers and distributors to increase market reach.
  • Ongoing: Product innovation and development of new formulations.
  • Ongoing: International market expansion to tap into new sources of revenue.
  • Ongoing: Increased consumer awareness and education campaigns to drive demand.

Riesgos

  • Potential: Increased competition from larger nutraceutical companies.
  • Potential: Changes in regulatory requirements for dietary supplements.
  • Potential: Fluctuations in raw material prices.
  • Potential: Negative publicity regarding the safety or efficacy of astaxanthin or spirulina.
  • Ongoing: Negative profit margin and limited financial resources.

Oportunidades de crecimiento

  • Expansion of Online Sales Channels: Cyanotech can capitalize on the growing e-commerce trend by expanding its online sales channels. The global e-commerce market is projected to reach trillions of dollars by 2026. By investing in its online presence, improving its website user experience, and leveraging digital marketing strategies, Cyanotech can reach a broader customer base and increase sales. This includes direct-to-consumer sales and partnerships with online retailers. Timeline: Ongoing.
  • Strategic Partnerships and Distribution Agreements: Forming strategic partnerships with major retailers and distributors can significantly expand Cyanotech's market reach. Collaborating with established players in the health and wellness industry can provide access to new markets and customer segments. This includes partnerships with grocery chains, pharmacies, and specialty health stores. Timeline: Ongoing.
  • Product Innovation and New Product Development: Investing in research and development to create new and innovative products can drive growth. This includes exploring new applications for astaxanthin and spirulina, as well as developing new formulations and delivery methods. The market for innovative dietary supplements is constantly evolving, and Cyanotech can stay ahead of the curve by introducing novel products that meet consumer needs. Timeline: Ongoing.
  • International Market Expansion: Expanding into international markets represents a significant growth opportunity for Cyanotech. The global dietary supplements market is growing rapidly, particularly in emerging economies. By targeting specific regions with tailored marketing strategies and distribution networks, Cyanotech can tap into new sources of revenue and diversify its customer base. Timeline: Ongoing.
  • Increased Consumer Awareness and Education: Investing in consumer education and awareness campaigns can drive demand for Cyanotech's products. Many consumers are not fully aware of the health benefits of astaxanthin and spirulina. By educating consumers about the science behind these ingredients and their potential health benefits, Cyanotech can increase demand and build brand loyalty. This includes content marketing, social media engagement, and partnerships with health influencers. Timeline: Ongoing.

Oportunidades

  • Expansion into new international markets.
  • Development of new products and formulations.
  • Increased consumer awareness of the health benefits of astaxanthin and spirulina.
  • Strategic partnerships with major retailers and distributors.

Amenazas

  • Increased competition from larger nutraceutical companies.
  • Changes in regulatory requirements for dietary supplements.
  • Fluctuations in raw material prices.
  • Negative publicity regarding the safety or efficacy of astaxanthin or spirulina.

Ventajas competitivas

  • Proprietary cultivation and extraction processes.
  • Established brand recognition for BioAstin and Spirulina.
  • Location in Hawaii provides a unique selling proposition (USP).
  • Long-standing relationships with distributors and retailers.

Acerca de CYAN

Cyanotech Corporation, established in 1983 and headquartered in Kailua-Kona, Hawaii, focuses on the cultivation, production, and sale of natural products derived from microalgae. The company's flagship products include BioAstin Hawaiian Astaxanthin, a dietary antioxidant known for enhancing skin health and supporting eye, joint, and immune function. This product is marketed as a human dietary supplement and dietary ingredient. Another key product is Hawaiian Spirulina Pacifica, a nutrient-rich dietary supplement, promoted for its energy-boosting, immune-strengthening, and cardiovascular benefits, as well as its antioxidant carotenoid content. Cyanotech distributes its products through a variety of channels, including distributors, retailers, and online platforms, directly targeting consumers. Additionally, the company engages in bulk sales to manufacturers, formulators, and distributors within the health foods, nutraceuticals, and dietary supplement industries. The company also provides contract extraction services. Cyanotech's commitment to producing high-quality, microalgae-based products has allowed it to establish a presence in the competitive health and wellness market.

Qué hacen

  • Cultivates and produces microalgae.
  • Extracts and processes astaxanthin from microalgae.
  • Manufactures and packages dietary supplements.
  • Sells BioAstin Hawaiian Astaxanthin for skin, eye, joint, and immune health.
  • Sells Hawaiian Spirulina Pacifica for energy, immune support, and cardiovascular benefits.
  • Provides contract extraction services.

Modelo de Negocio

  • Cultivation and production of microalgae-derived products.
  • Direct-to-consumer sales through online channels.
  • Sales through distributors and retailers.
  • Bulk sales to manufacturers and formulators.

Contexto de la Industria

Cyanotech Corporation operates within the consumer defensive sector, specifically in the packaged foods industry, focusing on dietary supplements. The global dietary supplements market is experiencing steady growth, driven by increasing health awareness and an aging population. Key trends include the rising demand for natural and organic products, as well as the growing popularity of online retail channels. Cyanotech faces competition from other players in the nutraceuticals market. Competitors include companies that offer similar algae-based products and broader dietary supplement brands. The company's success depends on its ability to differentiate its products through quality, branding, and effective marketing.

Clientes Clave

  • Health-conscious consumers seeking natural supplements.
  • Individuals looking for antioxidant and immune support.
  • Manufacturers and formulators in the health foods and nutraceuticals industries.
  • Retailers and distributors in the dietary supplement market.
Confianza de la IA: 71% Actualizado: 16 mar 2026

Finanzas

Gráfico e información

Precio de la acción de Cyanotech Corporation (CYAN): Price data unavailable

Últimas noticias

Consenso de analistas

Calificación de Consenso

Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para CYAN.

Objetivos de Precios

Análisis del precio objetivo de Wall Street para CYAN.

MoonshotScore

40/100

¿Qué significa esta puntuación?

El MoonshotScore califica el potencial de crecimiento de CYAN en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.

Liderazgo: Matthew Keith Custer

CEO

Matthew Keith Custer serves as the CEO of Cyanotech Corporation, overseeing the company's operations and strategic direction. Information regarding his detailed career history, education, and previous roles is not available in the provided source data. As CEO, he is responsible for managing the company's 77 employees and driving its growth in the competitive nutraceuticals market. His leadership is crucial for navigating the challenges and opportunities facing Cyanotech in the evolving health and wellness industry.

Historial: Due to the limitations of the provided source data, specific achievements, strategic decisions, and company milestones under Matthew Keith Custer's leadership cannot be detailed. His tenure and impact on Cyanotech's performance require further investigation beyond the available information. Assessing his track record would involve analyzing the company's financial performance, product innovation, and market share growth during his time as CEO.

Información del mercado OTC de CYAN

The OTC Other tier represents the lowest tier of the OTC market, indicating that Cyanotech Corporation may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited financial disclosure, which increases investment risk. Trading on the OTC Other market typically involves less stringent listing requirements compared to major exchanges like the NYSE or NASDAQ, resulting in potentially less transparency and regulatory oversight. Investors should exercise caution and conduct thorough due diligence before investing in companies on this tier.

  • Nivel OTC: OTC Other
  • Estado de divulgación: Unknown
Liquidez: Liquidity on the OTC market can be highly variable. Given that Cyanotech trades on the OTC Other tier, it's likely that the stock experiences lower trading volumes and wider bid-ask spreads compared to stocks listed on major exchanges. This can make it more difficult to buy or sell shares quickly and at desired prices. Investors should be prepared for potential price volatility and limited liquidity when trading CYAN.
Factores de riesgo OTC:
  • Limited financial disclosure due to the OTC Other tier.
  • Lower trading volume and liquidity compared to major exchanges.
  • Potential for wider bid-ask spreads.
  • Increased price volatility.
  • Less stringent regulatory oversight.
Lista de verificación de diligencia debida:
  • Verify the company's financial statements and SEC filings (if any).
  • Research the company's management team and their track record.
  • Assess the company's business model and competitive landscape.
  • Evaluate the company's revenue and earnings growth potential.
  • Analyze the company's cash flow and debt levels.
  • Understand the risks associated with investing in OTC stocks.
  • Consult with a financial advisor before making any investment decisions.
Señales de legitimidad:
  • The company has been in operation since 1983.
  • Cyanotech has established brand recognition for BioAstin and Spirulina.
  • The company has a direct-to-consumer sales channel.
  • Cyanotech has a physical presence with its headquarters in Kailua-Kona, Hawaii.

Lo Que los Inversores Preguntan Sobre Cyanotech Corporation (CYAN)

¿Cuáles son los factores clave para evaluar CYAN?

Cyanotech Corporation (CYAN) actualmente tiene una puntuación IA de 40/100, indicando puntuación baja. Fortaleza clave: Established brand recognition for BioAstin and Spirulina.. Riesgo principal a monitorear: Potential: Increased competition from larger nutraceutical companies.. Esto no es asesoramiento financiero.

¿Qué es el MoonshotScore de CYAN?

CYAN actualmente puntúa 40/100 (Grado D) en el MoonshotScore, lo que sugiere calificación baja. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.

¿Con qué frecuencia se actualizan los datos de CYAN?

Los precios de CYAN se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.

¿Qué dicen los analistas sobre CYAN?

La cobertura de analistas para CYAN incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.

¿Cuáles son los riesgos de invertir en CYAN?

Las categorías de riesgo para CYAN incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Increased competition from larger nutraceutical companies.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.

¿Cuál es la relación P/E de CYAN?

La relación P/E para CYAN compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.

¿Está CYAN sobrevalorada o infravalorada?

Determinar si Cyanotech Corporation (CYAN) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.

¿Cuál es el rendimiento por dividendo de CYAN?

Cyanotech Corporation (CYAN) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.

Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.

Recursos Oficiales

Análisis actualizado el Puntuación de IA actualizada diariamente
Fuentes de Datos y Metodología
Datos de mercado proporcionados por Financial Modeling Prep y Yahoo Finance. Análisis de IA por algoritmos propietarios de Stock Expert AI. Indicadores técnicos mediante cálculos estándar de la industria. Última actualización: .

Datos proporcionados solo con fines informativos.

Notas de análisis
  • Limited information available on CEO's background and track record.
  • OTC analysis based on general characteristics of the OTC Other tier.
Fuentes de datos

Popular Stocks